PRAX
$303.38
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Recent News
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization?
Praxis Precision Medicines recently reported that, by the end of 2025, it held US$926.00 million in cash and investments, supported by a US$621.00 million financing that extends its funding runway into 2028. At the same time, the company has filed FDA new drug applications for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation, signaling a possible shift from pure R&D focus toward commercial operations in central nervous system disorders. Now we’ll examine how this...
Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best hot stocks to buy according to analysts. On February 19, Praxis Precision Medicines reported the financial results for Q4 2025, ending 2025 with $926 million in cash & investments. Following an additional $621 million financing in January, the company’s cash runway is now expected to […]
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.